Our Approach Matters
While HEOR methodologies have advanced significantly, conventional healthcare decision making tools often fall short in accounting for contextual feasibility, system-level barriers, and implementation fidelity. These limitations hinder the ability to project real-world impact, especially as global pricing mechanisms, such as International Reference Pricing (IRP) and the Most Favored Nation (MFN) rule, demand increasingly robust and actionable evidence.​
​
EviGen was created to bridge this methodological gap. ​
​
By operationalizing principles of Implementation Science within economic and outcomes modeling, we enable biopharma and health policy stakeholders to move beyond theoretical models toward evidence that is translatable, testable, and ready for regulatory and payer scrutiny.
Our Approach Leads to:
Higher Acceptance on HTA Submissions
HTA bodies using frameworks like the HTA Core Model® benefit from early, consistent, and transparent evidence planning, resulting in more robust and successful submissions. 1
Early Scientific Advice Leads to Better Outcomes
Engaging early with HTA or payer bodies ensures your trial design, economic modeling, and RWE strategies are aligned, boosting credibility and increasing approval likelihood. 2,5
Real-World Roadblocks Stall Uptake in ~50% of Cases
System, provider, and patient-level barriers were found to significantly impede the uptake of new medicines, even high-value therapies, often resulting in half of approved treatments failing to reach expected adoption. 3,4
-
EUnetHTA. (2016). ​
-
HTA Core Model® version 3.0. European Network for Health Technology Assessment. https://www.eunethta.eu/hta-core-model/Facey, K., Rannanheimo, P., Batchelor, L., Borchardt, M., de Cock, J., Hirschberg, I., ... & Warner, K. (2020). ​
-
Real-world evidence to support Payer/HTA decisions about highly innovative technologies in the EU—actions for stakeholders. International Journal of Technology Assessment in Health Care, 36(4), 459-468. https://doi.org/10.1017/S0266462320000636Chambers, J. D., Thorat, T., Pyo, J., Chenoweth, M., & Neumann, P. J. (2019).
-
Despite high prices for specialty drugs, patients' out-of-pocket burden is not always greater. Health Affairs, 38(5), 731–736. https://doi.org/10.1377/hlthaff.2018.05147Sorenson, C., Drummond, M., & Kanavos, P. (2008).
-
Ensuring value for money in health care: The role of health technology assessment in the European Union. World Health Organization, on behalf of the European Observatory on Health Systems and Policies. https://www.euro.who.int/__data/assets/pdf_file/0011/98291/E91271.pdfHenshall, C., Schuller, T., & Mardhani-Bayne, L. (2016).
-
Using early dialogue to facilitate the adoption of new technologies. Nature Reviews Drug Discovery, 15, 811–812. https://doi.org/10.1038/nrd.2016.211
